To determine the relation of gray matter (GM) and white matter (WM) brain volumes, and WM lesion load, with clinical outcomes 20 years after first presentation with clinically isolated syndrome suggestive of multiple sclerosis (MS).   more »

Participants were 156 patients with relapsing-remitting MS. We compared the number of relapses during and after the war with similar time periods at the preceding year. Exposure to war events and resulting subjective stress were evaluated by means    more »

Research published by the UK MS Society has revealed that one in three GPs is unsure how to spot the signs of multiple sclerosis (MS). The report undertaken by Brand Health International questioned GPs   more »

A healthy male infant (2.68 kg, Apgars 9 and 10) was born at 36 weeks gestation by cesarean section, under general anesthetic. This is the fifth reported case of intrathecal   more »

The aim of the present study was to explore variations in functioning and disability - with regard to cognition, manual dexterity, walking, energy, mood, activities of daily living and social / lifestyle   more »

Laquinimod is a novel once-daily, orally administered immunomodulatory compound developed as a disease modifying treatment for   more »

has identified novel sets of genes that it believes will form the basis of a new assay to diagnose multiple sclerosis (MS), a disease of the central   more »

A short-term, very-high dose regimen of the immune-suppressing drug cyclophosphamide seems to slow progression of multiple sclerosis (MS) in most of a small group of patients studied and   more »

Opexa Therapeutics, Inc. (NASDAQ:OPXA), a cell therapy development and commercialization company, announced favourable safety and efficacy data for Tovaxin®, the Company's investigational T-cell vaccination   more »

Peptimmune, Inc. a privately held biotechnology company, announced that physicians have treated the first participant in a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary   more »

A new type of pill for relapsing-remitting multiple sclerosis (MS) has led to a 40 percent reduction in lesions and inflammation. The experts are hoping that the oral medication, which goes by the name laquinimod, could potentially be a significant advance, a   more »

The compounds discovered by Bionomics, around which the collaboration will focus, target the potassium ion channel Kv1.3. Kv1.3 is a key modulator of the immune system and it is a target found on human immune cells which are associated with nerve cell damage in patients with MS. Inhibitors of Kv1.3 have been   more »

Researchers from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health (NIH), have identified a promising new target   more »

Using imaging techniques, researchers have revealed the dynamic processes that allow receptors to communicate with one another to stimulate the immune system. By understanding this “crosstalk” researchers expect to gain insights into autoimmune   more »

Recently Human Genome Sciences (HGS) stated they were going ahead with several of their new drugs and they are planning to test LymphoStat-B, an experimental lupus drug, on Multiple Sclerosis (MS). The company feels the drug may also be effective on   more »